A phase II study of SMP-105 (BCG-CWS) in patients with advanced cancers refractory to the standard treatment
Phase 2
- Conditions
- Malignant tumors
- Registration Number
- JPRN-UMIN000009922
- Lead Sponsor
- Kobe Haborland Immunotherapy Clinic
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
1) Patients with severe complications(infectious disease, interstitial pneumonitis, cardiac disease, renal disease, hepatic disease, and uncontrolled diabetes mellitus). 2) Patients with autoimmune disease (scleroderma, Sjogren's syndrome, idiopathic thrombocytopenic purpura, multiple sclerosis, rheumatoid arthritis, and so on). 3) Patients who need the treatment with corticosteroids and immune-suppressive agents during this study (The use of their local and inhaled administration and non-steroidal anti-inflammatory agents is permitted). 4) Pregnant, lactating, or potentially to be pregnant. 5) Patients judged inappropriate for this study by responsible investigators.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method